A New Approach for Development of Vaccine Against Visceral Leishmaniasis: Lipophosphoglycan and Polyacrylic Acid Conjugates

dc.contributor.author Allahverdiyev, Adil M.
dc.contributor.author Koc, Rabia Cakir
dc.contributor.author Bagirova, Melahat
dc.contributor.author Elcicek, Serhat
dc.contributor.author Baydar, Serap Yesilkir
dc.contributor.author Oztel, Olga Nehir
dc.contributor.author Akdeste, Zeynep
dc.date.accessioned 2025-09-25T10:39:14Z
dc.date.available 2025-09-25T10:39:14Z
dc.date.issued 2017
dc.description Dincer Isoglu, Sevil/0000-0002-6887-6549; Cakir, Rabia/0000-0002-8545-9878; Allahverdiyev, Adil M./0000-0002-7031-5986; Yesilkir Baydar, Serap/0000-0001-6311-4302; Mustafaeva, Zeynep/0000-0002-4352-7617; Canim Ates, Sezen/0000-0003-2196-7053; Topuzogullari, Murat/0000-0003-4435-7776 en_US
dc.description.abstract Objective: To determine the antileishmanial vaccine effectiveness of lipophosphoglycan (LPG) and polyacrylic acids (PAA) conjugates on in vivo mice models. Methods: LPG molecule was isolated and purified from large-scale Leishmania donovani parasite culture. Protection efficacies of LPG alone, in combination with Freund's adjuvant, in a physical mixture and in conjugate (consisting of various LPG concentrations) with PAA, were comparatively determined by various techniques, such as cultivation with the micro-culture method, assessment of in vitro infection rates of peritoneal macrophages, determination of parasite load in liver with Leishman-Donovan Units, and detection of cytokine responses. Results: Obtained results demonstrated that the highest vaccine-mediated immune protection was provided by LPG-PAA conjugate due to all parameters investigated. According to the Leishman-Donovan Units results, the sharpest decline in parasite load was seen with a ratio of 81.17% when 35 mg LPG containing conjugate was applied. This value was 44.93% for the control group immunized only with LPG. Moreover, decreases in parasite load were 53.37%, 55.2% and 65.8% for the groups immunized with 10 mg LPG containing LPG-PAA conjugate, a physical mixture of the LPG-PAA, and a mixture of LPG + Freund's adjuvant, respectively. Furthermore, cytokine results supported that Th1 mediated protection occurred when mice were immunized with LPG-PAA conjugate. Conclusions: It has been demonstrated in this study that conjugate of LPG and PAA has an antileishmanial vaccine effect against visceral leishmaniasis. In this respect, the present study may lead to new vaccine approaches based on high immunogenic LPG molecule and adjuvant polymers in fighting against Leishmania infection. en_US
dc.description.sponsorship TUBITAK [1085170SBAG-4007] en_US
dc.description.sponsorship It is financially supported by TUBITAK (1085170SBAG-4007). en_US
dc.identifier.doi 10.1016/j.apjtm.2017.09.001
dc.identifier.issn 1995-7645
dc.identifier.issn 2352-4146
dc.identifier.scopus 2-s2.0-85030166844
dc.identifier.uri https://doi.org/10.1016/j.apjtm.2017.09.001
dc.identifier.uri https://hdl.handle.net/20.500.12573/3107
dc.language.iso en en_US
dc.publisher Wolters Kluwer Medknow Publications en_US
dc.relation.ispartof Asian Pacific Journal of Tropical Medicine en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Leishmania en_US
dc.subject LipoPhosphoglycan en_US
dc.subject Vaccine en_US
dc.subject Polymer en_US
dc.subject Polyacrylic Acid en_US
dc.title A New Approach for Development of Vaccine Against Visceral Leishmaniasis: Lipophosphoglycan and Polyacrylic Acid Conjugates en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Dincer Isoglu, Sevil/0000-0002-6887-6549
gdc.author.id Cakir, Rabia/0000-0002-8545-9878
gdc.author.id Allahverdiyev, Adil M./0000-0002-7031-5986
gdc.author.id Yesilkir Baydar, Serap/0000-0001-6311-4302
gdc.author.id Mustafaeva, Zeynep/0000-0002-4352-7617
gdc.author.id Canim Ates, Sezen/0000-0003-2196-7053
gdc.author.id Topuzogullari, Murat/0000-0003-4435-7776
gdc.author.scopusid 6505798127
gdc.author.scopusid 55164707900
gdc.author.scopusid 7801529589
gdc.author.scopusid 37110768700
gdc.author.scopusid 50360995200
gdc.author.scopusid 37111307900
gdc.author.scopusid 16744519800
gdc.author.wosid Bagirova, Melahat/Jzt-7307-2024
gdc.author.wosid Topuzogullari, Murat/Aac-7903-2019
gdc.author.wosid Öztel, Olga/Aax-2767-2020
gdc.author.wosid Allakhverdiev, Adil/Isu-9244-2023
gdc.author.wosid Canim Ates, Sezen/Gpt-0579-2022
gdc.author.wosid Cakir, Rabia/Acw-5799-2022
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department Abdullah Gül University en_US
gdc.description.departmenttemp [Allahverdiyev, Adil M.; Koc, Rabia Cakir; Bagirova, Melahat; Baydar, Serap Yesilkir; Oztel, Olga Nehir; Abamor, Emrah Sefik; Topuzogullari, Murat; Akdeste, Zeynep] Yildiz Tech Univ, Dept Bioengn, Istanbul, Turkey; [Elcicek, Serhat] Firat Univ, Dept Bioengn, Elazig, Turkey; [Ates, Sezen Canim] Yeni Yuzyil Univ, Biomed Engn, Istanbul, Turkey; [Dincer, Sevil Isoglu] Abdullah Gul Univ, Mat Sci & Nanotechnol Dept, Istanbul, Turkey en_US
gdc.description.endpage 886 en_US
gdc.description.issue 9 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q2
gdc.description.startpage 877 en_US
gdc.description.volume 10 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q3
gdc.identifier.openalex W2754683247
gdc.identifier.pmid 29080616
gdc.identifier.wos WOS:000417215100006
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.downloads 3
gdc.oaire.impulse 3.0
gdc.oaire.influence 2.6678284E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Leishmania
gdc.oaire.keywords Lipophosphoglycan
gdc.oaire.keywords Polymer
gdc.oaire.keywords Vaccine
gdc.oaire.keywords Polyacrylic acid
gdc.oaire.popularity 7.7983E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.oaire.views 3
gdc.openalex.collaboration National
gdc.openalex.fwci 1.1781
gdc.openalex.normalizedpercentile 0.81
gdc.opencitations.count 12
gdc.plumx.crossrefcites 11
gdc.plumx.mendeley 53
gdc.plumx.pubmedcites 4
gdc.plumx.scopuscites 15
gdc.scopus.citedcount 15
gdc.wos.citedcount 14
relation.isOrgUnitOfPublication 665d3039-05f8-4a25-9a3c-b9550bffecef
relation.isOrgUnitOfPublication.latestForDiscovery 665d3039-05f8-4a25-9a3c-b9550bffecef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
A new approach for development of vaccine against visceral leishmaniasis- Lipophosphoglycan and polyacrylic acid conjugates.pdf
Size:
620.81 KB
Format:
Adobe Portable Document Format
Description:
Makale Dosyası

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: